费森尤斯通过收购 新一代容量治疗 法玛西亚普强的营 产品上市 养部, 成立费森尤 Launch of a 斯卡比 new generation Formation of of hydroxyethyl Fresenius Kabi starch for Blood (acquisition of the Volume infusion solutions Substitution business of Pharmacia & Upjohn)
引入 氨基酸产品
容量治疗药物的引 入: 贺斯 Introduction of Novel amino acid solution Development of innovative solution for Blood Volume
家庭医疗护理的 首个方便喂食 ® 管道-瑞素 的引 建立 入 Establishment of outpatients Introduction of supply concept first ready-to-use tube feed Fresubin ®
Rejection of Transplant/Organs Chronic Organ Failure
费森尤斯集团 - 1992-2007 销售额 和 息税前利润
Fresenius Group – Sales Income & EBIT Development 1992 - 2007
单位：百万欧元 MEURO
成功的发展历程
Successful Development
1462 1997
1999
1999
1999
2000
2004/ 2005
1%静安 费森尤 斯 Propofol1% Fresenius
费森尤斯卡比 Fresenius Kabi
万汶® Voluven ®
卡比汶® Kabiven ®
三腔袋卡汶上市 ，三合一肠外营 养混和液 Launch of 3Chamber Bag Kabiven ® all-inone total parenteral nutrient admixture
销售额
Sales Income
1650.00
Байду номын сангаас
息税前利润
EBIT
11,358
1,609
1485.00 1320.00
12000 10500 9000
10,777
1,444
1155.00
7500 6000 4500 3000
990.00 825.00 660.00 495.00 330.00
1500 0
治疗性输液 I.V. Drugs
通过对葡萄牙 Labesfal的收购加强 了公司在输液市场 的地位 Expansion of I.V. Drug product portfolio: Acquisition of Labesfal /Portugal
费森尤斯开始进入 麻醉领域 Launch of Propofol 1% Fresenius short-acting general I.V. anaesthetic agent
输液泵 Infusion pumps
医疗器槭
Medical Devices
可移动输液泵 Infusion disposables
静脉连通器 Venous-Access Devices
静脉输液治疗性药物 – 治疗性输液
Infusion Therapy Intravenously Administered Drugs – I.V. Drugs
生产网络和技术 - 全球化的生产网络
Production & Technologies – International Production Network
国际化的生产基地 Internation Plants 区域化的生产基地 Reginal Plans 综合生产中心 Compounding Centers 原料工厂 Raw Material Plants 输注治疗生产基地 Transfusion Technology Plants
Health Care Worldwide
费森尤斯集团 – 全球健康管理专家
费森尤斯集团组织结构
Fresenius Group Structure
费森尤斯生物技术 抗体/细胞治疗
Fresenius Medical Care
Fresenius Kabi
费森尤斯医疗
费森尤斯卡比
Fresenius Helios
`0 7
92 93
94
95 96
97
98 99
费森尤斯卡比
Fresenius Kabi Business Overview
我们的使命
Our Mission Value
我们的产品、我们的服务，以及我们员工的 承诺和努力都专注于院内、院外的重症和慢 性病患者
Our products, our services as well as the commitment and dedication of our employees are focused on the critically and chronically ill patient inside and outside the hospital
99 `0 0 `0 1 `0 2 `0 3 `0 4 `0 5 `0 6 `0 7 92 93 94 95 96 97 98
165.00 0.00
`0 0 `0 1
`0 2 `0 3
`0 4 `0 5 `0 6
持续年平均年增长率: 20 % CAGR: 20%
持续年平均增长率: 28 % CAGR: 28%
Latin America
4 % of total sales Compounded average growth rate: + 15 % * Sales distribution based on 2006 sales
Africa
2 % of total sales Compounded average growth rate: + 26 %
- 亚洲第一 -- 临床营养和人工胶体
No. 1 in clinical nutrition and artificial colloids in Asia
输液治疗
Infusion Therapy
- 外科 Surgery - 急诊 Emergency - 重症监护 Intensive Care
临床营养
输液治疗 – 胶体和基础溶液
Infusion Therapy Infusion Solutions – Colloids and Basic Solutions
输液治疗 - 输注方案 Infusion Therapy – Infusion Solutions
胶体 Colloids
胶体是用于保持血容量, 血动 力循环及血细胞膜氧气量正 常的血浆替代品 Colloids are blood volume substitutes to maintain blood volume, hemodynamic circulation and tissue oxygenation
英脱利匹特® Intralipid®
肠外营养-贺斯 Parenteral Nutrition - HES
肠内营养
家庭医疗护理
输液产品的范 首个脂肪乳产 围扩大 品由卡比上市 Expansion of infusion solutions product range Launch of first fat emulsion by Kabi Vitrum
Antibodies
Cell Therapy
Oncology Discipline Transplantation Medicine
Gene Therapy Transplantation Medicine Regenerative Medicine
Disease Category
Cancer Rejection of Organs
输液治疗 – 输液药物 Infusion Therapy – I.V. Drugs
治疗性输液 I.V. Drugs
麻醉药品 Anaesthetics 镇痛药 Analgetics 抗生素 Antibiotics / Antivirals
Accurate Safe Easy to Use
用于肿瘤及镇痛治疗的移动泵 Ambulatory Pumps for Oncology and Pain Therapy
麻醉及ICU注射泵 Syringe Pumps for Anaesthesia / ICU
Fresenius Group: - 稳固的市场领导地位 快速发展的市场 Sales Distribution* Emerging Markets – Strong Market Positions and Compounded Average Growth Rate by Region 1998-2006
国际化的发展 International Expansion
加大新兴市场投 入, 在南非和捷克开 展收购; 澳大利亚成 立合资公司
Acceleration of business expansion in emerging markets, Strengthening of market positions with acquisitions in South Africa, Czech Republic and with a JV in Australia
我们的业务构成
Business in a Nutshell
院内及非住院护理的输液和营养治疗